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ABSTRACT 
Background:  MRI scores show promise for evaluation of Crohn's disease (CD) 
activity, although reported reproducibility is variable. Potentially, reproducibility could 
be improved by use of computer-assisted semi-automated measurements to reduce 
interobserver variation. The aim of this study was to develop and validate a predictive 
MRI activity score for ileocolonic CD activity based on computer-assisted semi-
automatic measurements of MRI features. 
Methods: An MRI based disease activity score (the "VIGOR" score) was developed 
using a purposeful selection of both subjective radiologist observation (mural T2 
signal) and semi-automatic measurements of bowel wall thickness, excess bowel 
wall volume and dynamic contrast enhancement (initial slope of increase; ISI) using a 
retrospective cohort of 27 patients with known CD against a Crohn's Disease 
Endoscopic Index of Severity (CDEIS) reference standard. A second, subjective 
score was developed based on only on radiologist observations. For validation, both 
scores were applied by two observer groups to a dataset of 106 patients (59 female, 
median age 33) with known CD prospectively recruited from two centers, who 
underwent consecutive MRI and ileocolonoscopy with CDEIS scoring. Three existing 
MRI activity scores (MaRIA, London score and CDMI) were also applied. Correlation 
between the five MRI scores and CDEIS was tested using Spearman rank 
correlation. Interobserver agreement was evaluated using the intraclass correlation 
coefficient (ICC).  
Results:  The VIGOR score (17.1*ISI+0.2*excess volume+2.3*mural T2), developed 
subjective score, MaRIA, London score and CDMI all had comparable correlation to 
CDEIS (Ob1/2, r=0.58/0.59, 0.39/0.51, 0.40/0.43, 0.38/0.45 and 0.34/0.48, 
respectively). The VIGOR score, however, had a higher ICC compared to the other 
activity scores (0.81 vs. 0.44–0.59). Diagnostic accuracy for a segmental CDEIS ≥3 
of 80%–81% was seen for the VIGOR score, which was similar to the four other 
activity scores (70%–86%). 
Conclusions:  The new VIGOR score achieves comparable accuracy to 
conventional MRI activity scores, but with improved reproducibility, favoring its use 
for therapy evaluation and monitoring of disease activity. 
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What is current knowledge: 
 Subjectively evaluated MRI features combined into activity scores can be 
used to quantify disease activity in Crohn's disease patients.   
 MRI activity scores show promise for use in therapeutic evaluation and 
clinical trials, although varying degrees of reproducibility have been reported.  
 
What is new here: 
 The novel VIGOR score incorporates both subjectively evaluated MRI 
features and new semi-automatic measurements, particularly enhancement 
and bowel wall volume features. 
 The VIGOR score showed equivalent grading accuracy, but significantly 
improved reproducibility compared to existing MRI activity scores. 
 Using a predefined cut-off value, the VIGOR score shows good diagnostic 
accuracy, comparable with other activity scores. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
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Crohn's disease is an inflammatory bowel disease manifesting throughout the 
gastrointestinal tract, although particularly affecting the small bowel and colon. 
Magnetic resonance imaging (MRI) is increasingly used for diagnosis and 
phenotyping of Crohn's disease, because it is safe, non-invasive and has high 
accuracy for evaluating enteric disease and extramural complications [1]. Multiple 
MRI features such as wall thickness and T1/T2 bowel wall signal have been 
validated as biomarkers of Crohn's disease activity, demonstrating good correlation 
with endoscopic and histopathologic grading of inflammation [2–4].   
 
Several MRI disease activity scores have been developed and externally validated, 
combining multiple MRI features to predict overall disease activity [3–6]. These 
scores are currently slowly disseminating into clinical practice, although they are 
predominantly still employed as research tools. The Magnetic Resonance Index of 
Activity (MaRIA), for example, has been developed using the Crohn's Disease 
Endoscopic Index of Severity (CDEIS) as a reference standard. The MaRIA is based 
on quantitative measurement of relative bowel wall contrast enhancement (RCE) 
along with subjective evaluation of the presence of mural ulceration and abnormal T2 
signal [3]. Other indices, such as the London score and Crohn's Disease MRI Index 
(CDMI) also rely on qualitative grading of various features by reporting radiologists 
[4,6]. Before such scores can be widely adopted for evaluating disease activity and 
therapeutic monitoring, both high accuracy across the spectrum of disease severity, 
and good reproducibility between radiologists must be proven. The current literature, 
however, reports variable reproducibility for many features used in MRI activity 
scores [6,7]. Moreover, although MRI shows high accuracy for severe disease 
activity (91% accuracy), diagnostic performance drops considerably for mild disease 
or disease in remission (62% accuracy) [8]. 
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One potential solution to the current limitations of MRI activity scoring is to 
incorporate novel software solutions, which can automatically extract relevant 
features from the MRI data. As such, the observer variability as well as the risk of 
observer bias inherent to existing scores might be decreased [9]. Specifically, new 
MRI image processing methods are available which delineate regions of active 
disease based on segmentation techniques [10], providing semi-automatic  
measurements of bowel wall thickness and disease volume. Furthermore, software 
techniques have been developed which automatically extract perfusion parameters 
from motion corrected free-breathing dynamic contrast enhanced (DCE)-MRI [11].  
 
We hypothesized that a scoring system combining semi-automatic software 
measurements with conventional subjective radiologist scoring of MRI features can 
improve accuracy and reproducibility in comparison to existing MRI scores. 
Accordingly, our aim was to develop and validate a predictive MRI score for 
ileocolonic CD activity incorporating novel software assisted semi-automatic 
measurement of MRI features using an ileocolonoscopic standard of reference, and 
to compare its performance with existing MRI activity scores. 
 
METHODS 
Retrospective cohort 
For development of the scoring system, an independent cohort was used, consisting 
of 27 patients with known Crohn's disease undergoing MR enterography (MRE) and 
ileocolonoscopy (with segmental CDEIS scoring) within four weeks. Prior to MRE, a 
standardized small bowel preparation was used consisting of 4 hours fasting and 
1600 mL 2.5% Mannitol solution ingested over 1 hour before the scan. This cohort 
was recruited for a previous study [6]. Three patients were excluded from the original 
cohort, because no informed consent could be obtained for future research.  
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Prospective cohort 
Between October 2011 and September 2014, consecutive patients ≥ 18 years with 
suspected or known Crohn's disease and scheduled for ileocolonoscopy were 
recruited from two European tertiary referral centers for inflammatory bowel disease 
(1. Academic Medical Center (AMC), Amsterdam, the Netherlands, and 2. University 
College London Hospital (UCLH), London, United Kingdom). All included patients 
underwent MRE and ileocolonoscopy within two weeks. The Harvey-Bradshaw Index 
(HBI) was collected at the time of MRI [12].  
Patient exclusion criteria were contraindications to MRI (e.g. pacemakers, 
claustrophobia), a final diagnosis other than Crohn's disease, failure to comply with 
the oral contrast protocol (see below), >2 weeks between MRI and ileocolonoscopy, 
and insufficient bowel cleansing precluding accurate mucosal assessment. Ethical 
permission was obtained from both institutions’ medical ethics committee and written 
informed consent was obtained from all patients. 
 
MRI protocol  
In the prospective cohort, patients fasted for at least 4 hours before the examination 
and were instructed to drink a total of 2400 mL 2.5% Mannitol solution (Baxter, 
Utrecht, the Netherlands) split in two doses: 800 mL (3 hours prior to MRI) and 1600 
mL (1 hour prior to MRI), to achieve distension of both colonic and small bowel 
segments. MRI examinations were performed on a 3.0 T MRI unit (Ingenia/Achieva; 
Philips, Best, the Netherlands) in the supine position using a phased-array body coil. 
The MRI protocol used in both centers is outlined in table 1. The DCE sequence 
consisted of 300 consecutive volumetric acquisitions at a temporal resolution of 1.2 
seconds/volume. Intravenous gadolinium contrast was administered 60 seconds after 
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the start of the DCE sequence block using the standard contrast agent in the 
participating centers (Gadovist 1.0 mmol/L, Bayer Schering Pharma, Berlin, 
Germany; Dotarem 0.5 mmol/L, Guerbet, Paris, France). Following the DCE series, 
coronal and axial 3D T1-weighted spoiled gradient-echo (SPGE) images were 
acquired in the delayed phase (approximately 7 minutes after contrast injection). To 
reduce bowel peristalsis, three separate doses of 10 mg intravenous 
butylscopolamine bromide (Buscopan, Boehringer Ingelheim, Ingelheim, Germany) 
were administered during the examination. DCE images were mutually aligned using 
the registration method described by Li et al. [11,13]. 
  
Table 1    Protocol for MRI acquisition  
  
    
Plane Slice thickness  
(mm) 
FOV TR  
(ms) 
TE  
(ms) 
Flip  
angle   
  
Balanced GE Coronal 5 380x380 2.5 1.25 60 
  
  
BTFE dynamic Coronal 10 380x380 2-2.1 1 45 
  
  
T2-SSFSE Coronal 4 380x380 628-660 60 90 
  
  
T2-SSFSE Axial 4 400x400 759 119 90 
  
  
T2-w SSFSE fat saturation Axial 7 380x380 967-1314 50 90 
  
  
DCE sequence Coronal 2.5 380x380-439 2.9 1.8 15 
  
  
3D T1-w SPGE fat saturation Coronal 2 380x380-459 2.2-2.4 1.0-1.1 10 
  
  
3D T1-w SPGE fat saturation Axial 2 380x380 2.1-2.3 1.0-1.1 10 
  
                  
  
BTFE, balanced turbo field-echo; DCE, dynamic contrast enhanced; FOV, field of view; GE, gradient echo; SPGE, 
spoiled gradient-echo; SSFSE, single-shot fast spin echo; TE, echo time; TR, repetition time.   
 
Image analysis 
Scans from the retrospective cohort were all individually evaluated by four observers 
(C.Y.N., D.P., J.S., J.M.) resulting in four evaluations per dataset [6]. MRI 
examinations from the prospective cohort were evaluated using online viewer 
software (3Dnet Suite, Biotronics3D, London, UK) by two pairs of observers (Ob1: 
C.Y.N, J.S.; Ob2. D.P, S.T.) with extensive experience in MRE (>1100, >800, >500 
and >1500 examinations, respectively). The first pair of observers was from AMC, 
the second pair from UCLH. Each MRI dataset was independently evaluated by one 
observer from both pairs, resulting in two evaluations per dataset. Observers were 
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blinded to each other’s findings and clinical data.  
For both the retrospective and prospective cohorts, overall scan quality was first 
graded on a scale from 0 (non-diagnostic images) to 3 (diagnostic images without 
artefacts). Subsequently, the following five bowel segments were evaluated 
individually: the terminal ileum (most distal 20 cm of the ileum), ascending colon, 
transverse colon, descending/sigmoid colon and rectum. Segment distension, 
defined as the percentage of adequately distended bowel for diagnostic evaluation, 
was graded from 0 to 4 (< 20%, 20–40%, 40–60%, 60–80%, > 80%). Furthermore, 
all segments were evaluated regarding the MRI features included in three existing 
validated MRI disease activity scores (MaRIA, London and CDMI scores) (table 2). 
Subsequently, segmental MaRIA, London and CDMI scores were calculated for 
segments in the prospective dataset [3,4], as detailed in appendix 1.  
  Table 2 MRI features and grading categories   
              
  
MRI Features 
Grading score   
  0 1 2 3   
              
  London/CDMI           
  
Mural thicknessa 1–3 mm > 3–5 mm  > 5–7 mm > 7 mm 
  
  
Mural T2 signal Equivalent to 
normal bowel wall 
Minor increase in 
signal-bowel wall 
appears dark grey 
on fat saturated 
images 
Moderate increase 
in signal-bowel wall 
appears light grey 
on fat saturated 
images 
Marked increase in 
signal-bowel wall 
contains areas of 
white high signal 
approaching that of 
luminal content 
  
  
Perimural T2 signal Equivalent to 
normal mesentery 
Increase in 
mesenteric signal 
but no fluid 
Small fluid rim (≤ 2 
mm) 
Larger fluid rim (> 2 
mm) 
  
  
T1 enhancement Equivalent to 
normal bowel wall 
Minor enhancement 
- bowel wall signal 
greater than normal 
small bowel but 
significantly less 
than nearby 
vascular structures 
Moderate 
enhancement - 
bowel wall signal 
increased but 
somewhat less 
than nearby 
vascular structures 
Marked 
enhancement - 
bowel wall signal 
approaches that of 
nearby vascular 
structures 
  
  MaRIA 
        
  
  
Mural thickness in mma         
  
  
RCE         
  
  Edema Absent Present       
  Ulcers Absent Present       
              
  
a  Measured using electronic calipers       
  
              
  
MRI=magnetic resonance imaging, RCE=relative contrast 
enhancement 
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Semi-automatic measurements 
Using our online viewer system, the bowel’s centerline was indicated on MRI by each 
observer by manually placing a number of widely spaced points within the lumen of 
the bowel through the bowel segments (see details of segment selection below) on 
the post-contrast coronal T1-weighted SPGE sequence (figure 1). Subsequently, the 
inner and outer bowel wall surfaces of the affected bowel wall were automatically 
delineated using the active contour segmentation method from the 3DNetSuite post-
processing environment (Biotronics3D, London, United Kingdom; technical 
description in appendix 2) [10]. From this delineation the following automatic bowel 
wall thickness (ABWT) features were automatically obtained: maximum bowel wall 
thickness (mm), mean bowel wall thickness (mm) and excess bowel wall volume 
(mm3). The excess bowel wall volume was defined as the volume of the delineated 
region exceeding normal thickness, calculated from the automatic mean thickness of 
healthy segments (no activity on MRI/endoscopy) in the retrospective cohort. Each 
delineation of the diseased region was also used as a 3D region of interest on DCE 
images to extract the initial slope of increase (ISI) of the enhancement curve [11]1.  
These semi-automated measurements were performed in the following segments: (1) 
all segments in the retrospective cohort dataset (regardless of activity) (2) in active 
segments (defined as a >0 score on at least one subjective MRI feature) of the 
prospective cohort datasets, and (3) in all segments of a random subset of 50 
datasets of the prospective cohort (see power calculation in statistical analysis 
section below). 
 
                                                        
1 The initial slope of increase corresponds to the mathematically defined A1 feature 
in this reference paper. 
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Reference standard 
For the prospective cohort, ileocolonoscopy was performed within two weeks of MRI 
using a standard endoscope (model CF-160L, Olympus) by either a 
gastroenterologist or a senior resident in gastroenterology under direct supervision of 
a gastroenterologist. The endoscopist applied the CDEIS to evaluate endoscopic 
disease [14]. The endoscopist was blinded to findings on MRI, except for cases 
where a balloon-dilatation procedure was indicated. In these cases, the length of 
stenosis on MRI was used to determine the feasibility of balloon-dilatation.  
 
Model development 
Feature selection was based on a purposeful selection process through examination 
of features common to previously validated MRI activity scores (MaRIA, London 
score and CDMI). These features usually comprise three categories:  1. mural 
thickness, 2. contrast enhancement (either subjectively graded or quantified using 
RCE) and 3. T2 mural signal intensity (contained in the MaRIA as mural edema). 
Although other features have been included (perimural T2 signal, ulceration), these 
features did not occur in any other MRI activity score and as such were not deemed 
essential for the new model. 
Firstly, we considered all semi-automated models, i.e. including one semi-automatic 
mural thickness or volume measurement, the ISI contrast enhancement grade and 
one subjective T2 signal feature. A second pool of subjective models was formed by 
using one subjective feature for each of the three feature categories (i.e. not 
including semi-automatic features). 
 11 
From both the semi-automatic and the subjective models the ‘best’ model was 
selected using a previously described exhaustive search method for biomarker 
discovery [15]. In summary, this method evaluates all possible combinations of MRI 
features as candidate models for predicting CDEIS. Specifically, the rank correlation 
to CDEIS of each putative model was determined in the retrospective data using a 
50-fold bootstrap cross-validation [16]. Eventually, this procedure delivered two 
models: the top ranking semi-automatic model and the top ranking subjective model. 
These were termed the "VIGOR score" and the "subjective score", respectively. 
 
Validation of MRI activity scores 
The segmental VIGOR and subjective scores as well as the MaRIA, London score 
and CDMI scores were correlated for each observer against the segmental CDEIS 
reference standard in the prospective dataset (see statistical analysis section below). 
Segments with missing model features (i.e. due to being non-evaluable or unable to 
calculate semi-automatic features) were excluded, to provide a fair comparison 
between different models. Additionally, interobserver agreement and correlation to 
CDEIS were calculated for all overlapping active segments (i.e. deemed active by 
both observers).  
 
Diagnostic accuracy and per-patient scores 
A secondary analysis focused on diagnostic accuracy for segmental disease activity 
(defined as a CDEIS ≥3 [17]). Therefore, the five MRI scores were applied to bowel 
segments of 50 randomly selected patients (random number generation from within 
the complete set of complete studies). The subset sample size of 50 datasets was 
determined based on a power analysis using previous MRI performance data [6]. 
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Employing an α of 0.05 and a β of 0.20, expected colonic sensitivity of 0.4 and 
prevalence of 0.15, expected terminal ileum specificity of 0.8 and prevalence of 0.67, 
the necessary number of terminal ileum and colonic segments was calculated to be 
45 and 154 segments, respectively. Anticipating a segment exclusion of 10%, a total 
of 50 patient datasets was required. 
Sensitivity, specificity, positive predictive value, negative predictive value and 
diagnostic accuracy were calculated based on all segments of this subset. 
Segmental active disease on MRI was defined for the existing activity scores using 
the predetermined cut-off values (MaRIA, ≥7; London score, ≥4.1; CDMI, ≥3) [3,4]. 
Regarding the VIGOR and subjective scores the optimal cut-off points for detection 
of active disease were determined using receiver-operating characteristics (ROC) 
analyses performed on the retrospective training data. 
Per-patient MRI activity scores for both observers and global CDEIS were calculated 
by summing up segmental scores and dividing by the number of evaluated 
segments. Subsequently, a stenosis score was added to the per-patient CDEIS 
score if applicable [14]. For comparison, segmental scores' correlations to CDEIS 
and interobserver agreement were also determined in all segments of the 50-patient 
subset. 
 
Statistical analysis 
Previous data has shown that inclusion of healthy segments (zero-inflated data) in 
interobserver agreement calculation provides over optimistic estimates (). For this 
reason our primary analysis is based on active segments only (>0 score on at least 
one subjective MRI feature). Segmental and per-patient MRI scores were correlated 
to the segmental and global CDEIS, respectively, using Spearman rank correlation, 
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which were interpreted as follows: 0–0.20, very weak; ≥0.20–0.40, weak; ≥0.40–0.60, 
moderately; ≥0.60–0.80, strong; ≥0.80–1.00, very strong. Interobserver agreement 
was evaluated using weighted kappa values for ordinal data and intraclass 
correlation coefficients (ICC) for continuous data, using the following criteria for 
interpretation: 0–0.20, poor; 0.21–0.40, fair; 0.41–0.60, moderate; 0.61–0.80, good; 
0.81–1.00, very good [18]. Spearman correlation coefficients were compared using 
the Steiger Z-test for overlapping, dependent correlations [19]. ICC's were compared 
by calculating the variance through bootstrapping, after which paired Student's t-tests 
were performed. We considered a P-value of < 0.05 to indicate a statistically 
significant difference. Model development and validation were implemented with R 
Statistical language (v3.1.2, Vienna, Austria). Descriptive statistics were analyzed 
using SPSS 22 for Mac (SPSS, Chicago, USA). 
 
RESULTS 
Retrospective cohort 
The retrospective cohort consisted of 27 known Crohn's disease patients (127 
segments evaluable by radiologist and endoscopist). Eighteen segments (6 colon, 12 
rectum) were excluded from the analysis, due to severe artefacts (n=4), poor 
distension (n=7) and fecal residue (n=7). A further 42 segments were excluded, as 
semi-automatic features could not be derived in these segments for the following 
reasons: segment outside the DCE field-of-view (33/42), failed DCE registration 
(8/42) or failed segmentation (1/42). Of the 33 segments outside the DCE field-of-
view, 91% were either colonic (16/33) or rectal (14/33), which was expected for this 
retrospective cohort, as MRI preparation and sequences were not intended for 
colonic evaluation. 
 
Prospective cohort 
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A total of 158 patients were prospectively recruited (89 AMC, 69 UCLH). Of these, 52 
patients were excluded for the following reasons: diagnosis other than Crohn's 
disease (n=18), > 14 days between MRI and colonoscopy (n=7), failure to comply 
with the oral contrast protocol  (n=6), cancelled or aborted ileocolonoscopy (n=5), 
incomplete MRI protocol (n=14; e.g. missing sequences and incomplete imaging), 
insufficient bowel cleansing (n=1) and non-compliance to breathing commands due 
to language barrier (n=1). The final prospective study cohort consisted of 106 
patients (69 AMC, 37 UCLH), for which demographics and clinical characteristics are 
provided in table 3. Characteristics of the 50 patient randomly determined subset 
used for evaluation of diagnostic accuracy and per-patient scores can be found in 
appendix 3. One patient experienced abdominal pain and cramping after the MRI 
examination, both of which were successfully treated with simple analgesia. 
  Table 3 Clinical characteristics of the prospective cohort   
        
  Total no. of patients 106   
  Female, n (%) 59 (56)   
  Age at MRI (years), median (IQR) 33 (26–44)   
  Previous surgery, n (%) 42 (40)   
  Concomitant treatments     
      Anti-TNF antibodies, n (%)  30 (28)   
      Steroids, n. (%) of patients 18 (17)   
      Thiopurines, no. (%)  14 (13)   
      5-ASA, no. (%) of patients 19 (18)   
      Methotrexate, no. (%)  8 (8)   
  CRP (mg/L), median (IQR) 5 (1–13)   
  HBI, median (IQR) 5 (2–8)   
  CDEIS, median (IQR) 3.2 (0.5–6.4)   
  Montreal classification     
      Age at diagnosis (years), median (IQR) 22 (17–28)   
      Disease location     
         L1 ileal, n (%) 43 (41)   
         L2 colonic, n (%) 15 (14)   
         L3 ileocolonic, n (%) 48 (45)   
         L4 upper GI tract involvement, n (%) 4 (4)   
     Disease behavior     
         B1 inflammatory 54 (51)   
         B2 stricturing 36 (34)   
         B3 penetrating 16 (15)   
 15 
     Perianal involvement, n (%) 23 (22)   
  
5-ASA, 5-acetylsalicylic acid; CDEIS, Crohn's disease Endoscopic 
Index of Severity; CRP, C-reactive protein; GI, gastrointestinal; 
HBI, Harvey-Bradshaw Index; IQR, interquartile range; MRE, 
magnetic resonance enterography; TNF, tumor necrosis factor. 
  
Mean scan image quality (0–3) was 2.2 (SD: 0.6). Mean distension values for 
terminal ileum and colon were both 3.4 (SD: 0.7). Of included segments (evaluable 
on MRI by the radiologist and at endoscopic intubation), Ob1 and Ob2 identified 88 
and 95 active segments on MRI, respectively. In the 50-patient subset, a total of 230 
and 229 segments were included for Ob1 and Ob2, respectively. 
 
In active segments (>0 score on at least one subjective feature), the VIGOR score 
could be calculated in 83% (73/88) of segments for Ob1 and in 73% (69/95) for Ob2. 
In the 50-patient subset, the VIGOR score could be calculated in 73% (167/230) of 
segments for Ob1. When the rectum was excluded from the analysis, this rate 
increased to 87% (161/186). For observer 2, the VIGOR score could be evaluated in 
70% (161/229) of segments, which increased to 82% (153/187) after exclusion of the 
rectum. Details of segment inclusion and reasons for exclusion can be found in table 
4. 
  Table 4 Segment inclusions and exclusions                 
      
Active segments   Subset (n=50), all  
segments 
  Subset (n=50), 
terminal ileum and 
colon   
      Ob1 Ob2   Ob1 Ob2   Ob1 Ob2   
  Total no. of segments*   88 95   230 229   186 187   
                        
  Exclusions (%)   15 (17) 26 (27)   63 (27) 68 (30)   25 (13) 34 (18)   
  Outside DCE   3 7   42 40   12 13   
  Failed DCE registration   7 7   1 1   1 1   
  Fecal residue   3 1   6 6   2 2   
  Poor distension   0 2   6 6   3 3   
  Artefacts   0 2   0 1   0 1   
  Failed segmentation   2 7   8 14   7 14   
                        
  Included segments (%)   73 (83) 69 (73)   167 (73) 161 (70)   161 (87) 153 (82)   
  Terminal ileum   54 49   39 41   39 41   
  Ascending colon   9 9   44 41   44 41   
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  Transverse colon   4 2   39 38   39 38   
  Desc/sigmoid colon   6 9   39 33   39 33   
  Rectum   0 0   6 8   - -   
                        
  * All segments which could be evaluated by the radiologist and endoscopist.    
Model development 
The developed VIGOR and subjective models were: 
VIGOR score =  17.1 ×  ISI + 0.2 ×  excess volume + 2.3 ×  mural T2 
Subjective score =  0.03 ×  RCE +  0.9 ×  mural thickness (mm) +  3 ×  mural T2  
A VIGOR score of ≥ 5.6 was determined via ROC analysis as the optimal cut-off 
value for active disease (CDEIS ≥3). For the subjective score, the optimal cut-off 
value for active disease was ≥ 4.8. 
 
Model validation and comparison 
Correlations to CDEIS for each observer pair and interobserver agreement are 
presented in table 5. In active segments, the VIGOR score showed moderate 
correlations to CDEIS (Ob1/2: r=0.58/0.59). Weak-to-moderate correlations to CDEIS 
were seen for the subjective score (r=0.39/0.51), MaRIA (r=0.40/0.43), the London 
score (r=0.38/0.45) and the CDMI (r=0.34/0.48). Significant differences were seen for 
Ob1 between the VIGOR score and the subjective score (p=0.04), the London score 
(p=0.03), the CDMI (p=0.01), but not the MaRIA (p=0.05). For Ob2, no significant 
differences were seen (p=0.10–0.35). The VIGOR score showed a very good ICC 
(0.81), while other activity scores showed moderate ICC's (0.44–0.59) (table 5). 
Scatter plots for all scores between observers can be found in appendix 4. 
Table 5 Correlations between MRI activity scores and interobserver agreement of individual MRI 
features 
    
Observer 1 
(n=73)   
Observer 2 
(n=69)   
Interobserver agreement 
(n=56)   
  MRI features r p-Value   r p-Value   ICC (95% CI) p-Value   
  VIGOR score 0.58 <0.001   0.59 <0.001   0.81 (0.56–0.91) <0.001   
  Subjective score 0.39 0.001   0.51 <0.001   0.44 (0.21–0.63) <0.001   
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  MaRIA 0.40 0.001   0.43 <0.001   0.44 (0.21–0.63) <0.001   
  London score 0.38 0.001   0.45 <0.001   0.47 (0.24–0.65) <0.001   
  CDMI 0.34 0.003   0.48 <0.001   0.59 (0.40–0.74) <0.001   
  
MaRIA=Magnetic Resonance Index of Activity; MRI=Magnetic Resonance Imaging; VIGOR=Virtual 
Gastrointestinal Tract   
 
A complete table with subset and per-patient results can be found in appendix 5. 
On the 50-patient subset including all segments (active and in remission), the VIGOR 
score showed moderate correlation to CDEIS (Ob1/2, r=0.57/0.53) for segmental 
disease activity, while the correlations for the other activity scores ranged between 
0.50–0.61 for Ob1 and between 0.53–0.64 for Ob2. No significant differences were 
seen between the VIGOR score and other activity scores for Ob1 (p=0.2–0.6). For 
Ob2, the CDMI and London score showed significantly higher correlation to CDEIS 
compared to the other activity scores (p=0.02-0.03). The VIGOR score showed a 
very good ICC (0.87), while other activity scores showed good to very good ICC's 
(0.77–0.86).  
 
Per-patient activity scores on the 50-patient subset showed moderate correlations to 
CDEIS for the VIGOR score (Ob1/2, r=0.53/0.54), subjective score (r=0.60/0.57), 
MaRIA (r=0.58/0.51), London score (r=0.58/0.56) and CDMI (r=0.53/0.59). There 
were no significant differences between any pair of activity scores (p>0.05). The 
VIGOR per-patient scores showed a good ICC (0.77), which was not significantly 
different from other activity scores for which ICC's ranged between 0.71–0.79 
(p>0.05) (appendix 5).  
 
Diagnostic accuracy  
The diagnostic accuracy for segmental active endoscopic disease for the five MRI 
scores are presented in table 6. No significant differences in diagnostic accuracy 
were seen between different MRI activity scores (p>0.05), except for the subjective 
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scores' significantly lower accuracy for Ob1 compared to other activity scores 
(p<0.01). 
 
 
  
Table 6 Diagnostic accuracy for segmental MRI activity scores for detection of active disease 
(CDEIS≥3)       
    Observer 1         Observer 2         
    Sensitivity Specificity PPV NPV Accuracy Sensitivity Specificity PPV NPV Accuracy 
  VIGOR score 76% 84% 63% 90% 81%   74% 82% 58% 90% 80%   
  
Subjective 
score 78% 67% 47% 89% 70%   74% 82% 58% 90% 80%   
  MaRIA 67% 86% 64% 88% 81%   64% 91% 71% 88% 84%   
  
London 
score 60% 96% 84% 87% 86%   57% 94% 77% 86% 84%   
  CDMI 60% 92% 73% 86% 83%   62% 91% 72% 87% 83%   
                            
  PPV=Positive predictive value; NPV=Negative predictive value               
                            
 
 
DISCUSSION 
In this development and validation study, evidence is provided for a new MRI CD 
activity scoring system, the “VIGOR score”, incorporating both subjective 
observations and semi-automatic features. The VIGOR score achieved significantly 
improved reproducibility in segments with active disease in comparison to existing 
activity scores, such as the MaRIA, London score and CDMI, as well as a new 
subjective score based on the best performing combination of individual MRI features 
of activity. The VIGOR score showed the highest correlation with the endoscopic 
standard of reference, although there was no consistent statistically significant 
difference (for both observers) in comparison with the other activity scores. In a 
subset of 50 patients, the VIGOR score showed similar diagnostic accuracy 
compared to other activity scores. When both active and inactive segments were 
included, correlation to CDEIS and reproducibility were higher for subjective activity 
scores then when considering active segments only. Simultaneously, little changes 
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were observed for the VIGOR score. When considering the per-patient VIGOR score, 
correlation with CDEIS remained moderate and reproducibility remained good. 
MRI activity scores are currently being investigated for use as outcome measures in 
clinical trials, with some success [20,21]. Clearly, for use in multicenter studies, a 
high level of reproducibility between readers is imperative. Our study reports very 
encouraging performance characteristics for the newly developed semi-automatic 
model: correlation with CDEIS is at least as good as existing scores, yet 
interobserver agreement is considerably higher. Both wall thickness and 
enhancement are proven MRI biomarkers of disease activity, yet both suffer from 
subjectivity of measurement. By automating the process, this variability is 
significantly reduced. The next stage of development should now investigate the 
ability of the VIGOR score to monitor therapy via longitudinal studies, similar to work 
reported by Ordas et al. evaluating the MaRIA [21].  
Compared to existing evaluations of MRI activity scores, we found relatively low 
correlations with CDEIS [5,6,21], and lower levels of sensitivity for segmental active 
disease. We hypothesize that this is most likely caused by the disease spectrum in 
our prospective cohort, with relatively high prevalence of mild disease. This is 
confirmed by the median CDEIS, CRP and HBI values from our prospective cohort 
(table 3 and appendix 3), which are much lower than those in previous studies. [3,4].  
The presence of mural ulceration has been reported as very useful sign of activity 
and is incorporated as part of the MaRIA score. However data suggests that 
evaluation of ulceration on MRI is highly reader dependent [6]. For this reason, we 
did not include this feature in our model development. Furthermore, all five MRI 
scores (four of which did not include ulceration) achieved similar correlation to 
CDEIS and diagnostic accuracy for active segments.  
In our study, we performed separate analyses on active segments and in a subset of 
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patients, all segments, regardless of activity.  Our primary analysis was limited to 
active segments as large numbers of normal segments tend to skew correlative 
statistics and can result in over-optimistic conclusions. This is confirmed by our 
results; higher reproducibility was seen for subjective activity scores in the inclusive 
analyses of all segments (table 5 and appendix 5). 
In our study we reported generalized linear regression models, since these models 
are easy to apply, interpretable and understandable, and take advantage of the fact 
that most MRI features have positive linear relationship to Crohn's disease severity. 
However, we also tested Tobit regression models to account for zero-inflation of the 
data as well as random forest models to be independent from any relationship of the 
data. These models did not improve our results significantly, which is why we favor 
the easier interpretable and applicable generalized linear regression. We applied a 
heuristic feature selection using important feature categories from previous studies 
as the basis for model development. Our feature selection used a combination of 
subjective and semi-automatic features to fully employ the capabilities of MRI for 
disease evaluation.  
In the development and validation studies of the MaRIA score in particular, a rectal 
enema was used to distend the colon [3,5]. In the current study, we have shown that 
good image quality can also be achieved using an oral preparation with an additional 
800 mL of Mannitol solution 3 hours prior to the exam; readers graded colonic 
distension as generally good. Such a protocol may prove more acceptable to patients 
by removing the need for a rectal enema. Bowel preparation for the retrospective 
cohort did not include specific colon preparation. Segments with poor colonic/rectal 
distension or fecal residue were removed from the retrospective group as these 
might have introduced bias to the developed model. 
Our study has several limitations. The DCE sequence used in our retrospective 
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cohort used a smaller field of view compared to the sequence used in the 
prospective cohort, which limited the number of ISI data for model development. 
Because the field was positioned on the terminal ileum, the excluded segments were 
mainly colonic and rectum segments (81% of exclusions). Furthermore, in the 
prospective cohort, a relatively large number of rectum segments were excluded due 
to being out of the field-of-view on DCE. Semi-automatic software solutions together 
with MRI sequences continuously undergo improvement and as such, an increase in 
success-rate can be expected following iterations of development. However, our 
results do reveal the current limitations of semi-automatic features, as measurements 
in segments with suboptimal preparation were limited. Although subjective evaluation 
is also affected, human interpretation appears superior in coping with the effects of 
suboptimal preparation on mural thickness and contrast-enhancement.  
Currently, steps are being taken to optimize the time-efficiency of semi-automatic 
MRI measurements and to provide full integration in viewer software. Clearly, these 
aspects are essential for clinical applicability, which requires easy to use techniques.  
In conclusion, the use of semi-automatic features for assessment of patients with CD 
maintains diagnostic and grading accuracy, while improving reproducibility over 
conventional activity scores. This favors its use for therapy evaluation and monitoring 
of disease activity. Accurate and reproducible MRI scores could improve the 
physician's trust in these scores to make consistent and effective treatment 
decisions.  
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Figure 1 (A) Placement of centerline points in the lumen of an affected transverse 
colon segment. A few centerline points are placed in the middle of the lumen in one 
or more slices. (B) The delineation of the inner and outer bowel wall surfaces is 
visualized by a red line. Presently this is shown on a coronal slice, but it can be 
visualized in a similar way in reconstructed sagittal or transversal planes. 
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